CH-4002 Basel

Glivec ® approved in EU as first post-surgery therapy to reduce risk of cancer returning in patients with aggressive gastrointestinal tumors • Post-surgery use of Glivec shown to reduce the risk of gastrointestinal stromal tumors (GIST) returning by 89%1 • GIST are a rare, aggressive and potentially...

Full description

Bibliographic Details
Main Authors: Media Release, Communique Aux, Medias Medienmitteilung
Other Authors: The Pennsylvania State University CiteSeerX Archives
Format: Text
Language:English
Subjects:
Executive Vice President
Global Head
Novartis Oncology Development. Study details
Gist
Norway
Riva
Iceland
Online Access:http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.599.3769
http://hugin.info/134323/R/1311895/303983.pdf

Similar Items